Markets:

Overview

News

Currencies

International

Treasuries

Pharmather Hldgs Ltd (OP:PHRRF)

0.0870 +0.0010 (+1.16%)

Streaming Delayed Price Updated: 2:54 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pharmather Hldgs Ltd

< Previous 1 2 3 4 Next >

Parkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track ↗

May 03, 2023

Specialty pharmaceutical company PharmaTher Holdings (OTCQB: PHRRF) has submitted a Fast Track Application to the Food and D

Via Benzinga

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease

May 02, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More ↗

April 05, 2023

Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin...

Via Benzinga

MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update ↗

April 03, 2023

Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to...

Via Benzinga

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

April 03, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval ↗

March 30, 2023

PharmaTher Holdings Ltd.

Via Benzinga

PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease

March 29, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗

February 27, 2023

Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...

Via Benzinga

Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind ↗

February 22, 2023

Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through...

Via Benzinga

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More ↗

February 13, 2023

Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More

Via Benzinga

PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation ↗

February 07, 2023

Specialty ketamine company PharmaTher Holdings Ltd.

Via Benzinga

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System

February 07, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics ↗

February 06, 2023

Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically...

Via Benzinga

MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations ↗

February 06, 2023

Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve

Via Benzinga

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

February 06, 2023

From Revive Therapeutics Ltd.

Via GlobeNewswire

PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch ↗

February 03, 2023

Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items.

Via Benzinga

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

February 02, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease

February 01, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More ↗

January 25, 2023

Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?

Via Benzinga

Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News ↗

January 21, 2023

Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for...

Via Benzinga

Psychedelics Market Could Reach $12B By 2029, Says New Report ↗

January 19, 2023

A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before...

Via Benzinga

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

January 18, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products ↗

January 11, 2023

Two psychedelics companies have shared their updates and key milestones to be reached this 2023.

Via Benzinga

PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023

January 11, 2023

From PharmaTher Holdings Ltd.

Via GlobeNewswire

FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status ↗

December 15, 2022

The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation.

Via Benzinga

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

December 15, 2022

PharmaTher’s 4th FDA orphan drug designation for ketamine

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience

November 14, 2022

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder ↗

November 01, 2022

Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU)

Via Benzinga

PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome

November 01, 2022

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Ketamine for Parkinson's Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It ↗

October 05, 2022

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a pharmaceutical company focused on developing novel uses and delivery forms of ketamine

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.